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Background  
Randomised controlled trials (RCTs) are the study of choice to provide reference standard 
evidence for the efficacy of new or existing interventions for the management of Inflammatory 
Bowel Disease (IBD) (1,2). Their methodological approach to reduce the risk of bias (any 
departure from the truth) ensures that the true effects of the intervention are reported in a 
manner that can best represent clinical reality. 
In considering published RCTs, it is difficult to distinguish poor writing from poor research 
quality. Whilst studies all should report using the CONSORT guidance, released initially in 1995, 
many journals do not mandate this and often those that do simply confirm in a binary fashion 
(whether it is reported) rather than the appropriateness of what is recorded. As such, failing in 
such studies often leave readers having to assume poor reporting represents genuine bias. 
Whilst peer review can and should address this, there are long-standing concerns with the 
validity and reliability of this process with the field of academia, although it remains the best 
system and most used across publishing in the field.  
Quality is a glib concept, capriciously employed and often a subjectively understood term. It has 
been further complicated in the last decade with the hugely significant emergence of a 
consensus on rating quality of a whole evidence base for each outcome through the use of 
GRADE (3). When considering individual RCTs, definitions of quality have often also varied, but 
most describe ‘design and RCT conduct, to prevent systematic errors, or bias’ (4). Bias occurs 
when the results of a study do not represent the truth because of the inherent limitations in the 
design or conduct of a study (5). As such, considering the risk of such bias is key when judging 
an individual RCT and failures in key areas can significantly limit the potential impact of a study.  
The Cochrane risk of bias tool is employed across healthcare reviews to judge key elements 
which will be briefly summarised (6). Selection bias, which includes appropriate randomisation 
as its most obvious element, also includes the difficult to understand principle of allocation 
concealment. This was infamously demonstrated at the birth of the evidence base revolution 
over 25 years ago to lead to overestimates of treatment effect of close to 40% (7). This is best 
understood with an example. In an RCT investigating the use of biologic vs traditional oral 
therapies for IBD, an appropriate randomisation schedule may exist, and patients to be recruited 
from an outpatient setting. If the allocation schedule is available at recruitment, it is possible that 
a researcher who knows the next patient will be allocated a biologic therapy may choose not to 
recruit a subject who has difficult venous access. This sort of simple difference may lead to a 
systematic imbalance in the groups, with those patients with difficult venous access having a 
more complex historical course and being overrepresented in the control group. This example is 
key as it is not the same as blinding, which often is not possible for very practical reasons, but 
the concealment of the allocation schedule is always possible and a key source of potential 
bias. 
Performance bias, through blinding of participants and personnel and detection bias, through 
blinding of outcome assessment, are better understood. Attrition bias occurs from missing 
outcome data and the more that is missing or unexplained, the more there is a risk that issues 
with adverse effects, tolerability or other negative outcomes could be misrepresented when 
ignored. Reporting bias is equally problematic with reporting of only advantageous outcomes, 
reporting of post hoc analysis or indeed the lack of reporting of key outcomes further raising the 
risk of bias. 
A previous study of over 20,000 RCTs included in Cochrane reviews up to 2014 found that there 
was a trend towards improvement in all these key items of reporting (8). Within Inflammatory 
Bowel Disease, there is a relatively small evidence base on which treatments options emanate 
from and this is used to guide the treatment of hundreds of thousands of patients. In the last 5 
years, almost all IBD international guideline committees have embraced the GRADE approach 
for quality assessment and recommendations. The key to the GRADE approach to risk of bias is 
that it is considered at the outcome and not individual study level. This means that the presence 
of individual studies that are reported in a manner that renders them of low risk of bias cannot 
prevent the overall certainty of the evidence for a given outcome being downgraded by studies 
at higher risk of bias (3). The implications of this, now and moving forward, are not yet fully 
understood by the entire IBD research and peer-reviewing community, but suggests that it is 
more important now than ever before for all those producing and publishing RCTs to take all 
measures to report in a manner that is of low risk of bias, particularly as this allows true issues 
of quality to be separated from issues of reporting. This also ensures GRADE certainty of 
evidence can be the highest possible and not artificially impacted by such reporting issues. 
Objectives 
We set out to examine how reporting of these key elements of risk of bias within IBD RCT and 
factors associated with higher risk of bias through a systematic review of all IBD RCTs 
published since the Consort statement (1995). 
 
Methods 
To begin with, the systematic reviews will be searched for in the Cochrane library. 
Inclusion criteria for systematic reviews: 
Types of studies: Randomised controlled trails published since 1996 included in Cochrane 
reviews published by the Cochrane IBD group from March 2011 (launch of higgins criteria for 
risk of bias assessment - the last update of the Cochrane risk of bias reporting tool). 
Type of participants: Patients with either Crohn’s disease or Ulcerative colitis or a combination 
of the conditions to be included with all age groups and patients in any disease state to be 
considered. 
Types of interventions: Interventions for the induction, maintenance, or management of 
symptoms. Studies could involve any form of intervention compared to any other intervention, 
placebo, no treatment or usual care. Studies could include any outcome measures. 
Exclusion criteria for systematic reviews: 
Systematic reviews published before March 2011 or duplicates from an earlier version of an 
already included review. Reviews that did not utilise the Cochrane risk of bias tool were not 
included. 
 
Inclusion criteria for RCTs: 
We will include all primary RCTs included in all included SR reviews from 1995 till the date of 
the search (July 2019), corresponding with the release of the CONSORT statement for trial 
reporting. 
Exclusion criteria for RCTs: Quasi-randomised trials will be excluded 
Search methods for identification of studies  
We will use the latest update version of all titles included and will not include withdrawn titles or 
‘empty’ reviews. Cochrane review will be downloaded as a PDF file from the Cochrane Library. 
All the included studies’ publication characteristics and risk of bias assessment will be manually 
collected and recorded within a database file. Moreover, the PubMed and Web of Science 
databases will be downloaded with their list of indexed journals in addition to Journal Citation 
Reports. 
 
Data collection and analysis  
Data collection: 
Two authors (JK and MG) will independently review all titles and abstracts of potential trials and 
then potential studies will be accessed in full text. Any disagreements will be resolved by a third 
author. All journal articles chosen for full-text review will be evaluated independently again by 
two authors (JK and MG) to assess inclusion criteria to consider for analysis, with the third 
author resolving differences. Extraction of the references for all included RCTs will occur first, 
followed by manual validation to exclude duplicates and references which were encompassed in 
multiple reviews. 
Data extraction: 
From included full-text RCTs, data will be extracted independently by 2 authors (JK and MG) 
using a standardized form to record the risk of bias for each item within the Cochrane Higgins 
criteria, as discussed above. Additionally, key demographic and descriptive data will be 
extracted, included the year of publication, journal source, number of authors, funding source 
and number of study centres. 
A matching algorithm and manual validation will be used to standardise journal names and 
eliminate abbreviations. We will visit the website of each listed journal, if available, and 
extracted its up to date impact factor. The impact factor centile will then be collected from 
Journal Citation Reports.  
The aforementioned publication characteristics will then be combined with the collected risk of 
bias assessment for each RCT, and as such, will be categorised as “low”, “high”, or “unclear” for 
each key risk of bias items as per sequence generation, allocation concealment, blinding, 
incomplete outcome data reporting, and selective reporting. The most recent risk of bias 
assessment will be considered for RCTs that were encompassed in multiple Cochrane reviews.  
Analysis 
The data will be first analysed to assess the proportion of trials at high and unclear risk of bias. 
This will then used to determine the evolution of poor reporting over time, its association to 
impact factor (No IF, <5, 5-10, ≥10), centile of impact factor (No IF, <70th centile, 70-90th, ≥90th 
centile), funding source (industry and public sponsorship, public sponsorship, not specified, and 
industry), reported form (abstract, full text), study centre (single vs multi-centre), and number of 
authors (<5, 5-10, ≥10). 
Ethics  
Patients will not be involved at any stage of this study’s design or outcome as data will be 
collected from previously published studies and at no point will patients be recruited.  
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